These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18525030)

  • 1. Sarcoglycans take center stage in gene transfer therapy.
    Müller OJ; Lochmüller H
    Neurology; 2008 Jul; 71(4):234-5. PubMed ID: 18525030
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient page. Gene therapy and muscular dystrophies.
    Karceski S
    Neurology; 2008 Jul; 71(4):e6-8. PubMed ID: 18645160
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
    Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
    Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy.
    Baumeister SK; Todorovic S; Milić-Rasić V; Dekomien G; Lochmüller H; Walter MC
    Neuromuscul Disord; 2009 Feb; 19(2):167-71. PubMed ID: 19167890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency.
    Bartoli M; Poupiot J; Vulin A; Fougerousse F; Arandel L; Daniele N; Roudaut C; Noulet F; Garcia L; Danos O; Richard I
    Gene Ther; 2007 May; 14(9):733-40. PubMed ID: 17330087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
    Herson S; Hentati F; Rigolet A; Behin A; Romero NB; Leturcq F; Laforêt P; Maisonobe T; Amouri R; Haddad H; Audit M; Montus M; Masurier C; Gjata B; Georger C; Cheraï M; Carlier P; Hogrel JY; Herson A; Allenbach Y; Lemoine FM; Klatzmann D; Sweeney HL; Mulligan RC; Eymard B; Caizergues D; Voït T; Benveniste O
    Brain; 2012 Feb; 135(Pt 2):483-92. PubMed ID: 22240777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A.
    Bartoli M; Roudaut C; Martin S; Fougerousse F; Suel L; Poupiot J; Gicquel E; Noulet F; Danos O; Richard I
    Mol Ther; 2006 Feb; 13(2):250-9. PubMed ID: 16290124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional enhancement of skeletal muscle by gene transfer.
    Gregorevic P; Chamberlain JS
    Phys Med Rehabil Clin N Am; 2005 Nov; 16(4):875-87, vii-viii. PubMed ID: 16214049
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction and analysis of compact muscle-specific promoters for AAV vectors.
    Wang B; Li J; Fu FH; Chen C; Zhu X; Zhou L; Jiang X; Xiao X
    Gene Ther; 2008 Nov; 15(22):1489-99. PubMed ID: 18563184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cell biology of the sarcoglycan complex.
    Ozawa E; Mizuno Y; Hagiwara Y; Sasaoka T; Yoshida M
    Muscle Nerve; 2005 Nov; 32(5):563-76. PubMed ID: 15937871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors.
    Goehringer C; Rutschow D; Bauer R; Schinkel S; Weichenhan D; Bekeredjian R; Straub V; Kleinschmidt JA; Katus HA; Müller OJ
    Cardiovasc Res; 2009 Jun; 82(3):404-10. PubMed ID: 19218289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy. Safer and virus-free?
    Ferber D
    Science; 2001 Nov; 294(5547):1638-42. PubMed ID: 11721029
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.
    Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR
    Ann Neurol; 2010 Nov; 68(5):629-38. PubMed ID: 21031578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.
    Mendell JR; Rodino-Klapac LR; Rosales-Quintero X; Kota J; Coley BD; Galloway G; Craenen JM; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Viollet L; Walker CM; Sahenk Z; Clark KR
    Ann Neurol; 2009 Sep; 66(3):290-7. PubMed ID: 19798725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
    Bogdanovich S; McNally EM; Khurana TS
    Muscle Nerve; 2008 Mar; 37(3):308-16. PubMed ID: 18041051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice.
    Nishiyama A; Ampong BN; Ohshima S; Shin JH; Nakai H; Imamura M; Miyagoe-Suzuki Y; Okada T; Takeda S
    Hum Gene Ther; 2008 Jul; 19(7):719-30. PubMed ID: 18578595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for muscular disease.
    Johnston N
    Drug Discov Today; 2004 Sep; 9(18):777. PubMed ID: 15364061
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gene therapy in muscular dystrophy].
    Takeda S; Nabeshima Y
    Tanpakushitsu Kakusan Koso; 1995 Dec; 40(17):2765-71. PubMed ID: 8584734
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene delivery goes global.
    Thomas CE
    Nat Med; 2004 Aug; 10(8):782-3. PubMed ID: 15286775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.